Hims & Hers Shares Plunge as Amazon Enters Telehealth Arena

November 14, 2024, delivered a devastating blow to Hims & Hers Health investors as the company’s stock value collapsed by more than 25% in a single trading session. This dramatic sell-off was triggered by Amazon’s strategic move into the telehealth sector, directly challenging the core revenue streams that have driven Hims & Hers’ financial performance.

Amazon’s Direct Assault on High-Margin Services

The e-commerce behemoth launched a new telemedicine service exclusively for Prime members, featuring transparent flat-rate pricing across more than thirty healthcare categories. This initiative includes medical consultations, treatment plans, and complimentary medication delivery through Amazon Pharmacy. Crucially, Amazon is targeting the precise therapeutic areas—specifically male pattern hair loss and erectile dysfunction—that generate over 80% of Hims & Hers’ gross profit margins.

Market analysts immediately highlighted the competitive threat, noting Amazon’s pricing structure appears “significantly more attractive” for most treatments compared to existing Hims & Hers offerings. The tech giant leverages its enormous Prime subscriber network and established pharmaceutical distribution infrastructure, enabling aggressive pricing while maintaining service quality—a classic market disruption strategy.

Bank of America Delivers Severe Downgrade

The downward pressure intensified when Bank of America issued a stark reassessment of Hims & Hers’ prospects. Analyst Allen Lutz executed a rare double-downgrade, bypassing neutral ratings entirely to drop the stock from “Buy” directly to “Underperform.” Simultaneously, the firm slashed its price target nearly in half, reducing it from $32 to $18 per share.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Key concerns driving the downgrade:
• Amazon’s substantially more competitive pricing model
• Increased challenges in customer acquisition and retention
• New product launches now require exceptional performance
• Core business segments facing direct competitive pressure

Trading volume exploded to over 62 million shares on November 14—multiple times the normal average—as hundreds of millions in market capitalization evaporated within hours.

Questioning the Sustainability of Premium Margins

Hims & Hers had previously established a strong market position by connecting patients discreetly with licensed healthcare providers for sensitive medical conditions where privacy is often preferred over traditional clinic visits. This specialized approach supported premium pricing and rapid expansion.

Amazon’s market entry potentially disrupts this business model entirely. The technology conglomerate views healthcare as a strategic growth opportunity and can leverage existing customer relationships across its ecosystem. The central question has shifted from whether Amazon will capture market share to determining exactly how substantial that capture will be.